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ABSTRACT 
 
Background: Point-of-care devices (POCDs) for monitoring long-term oral anticoagulation therapy (OAT) may be a 
useful alternative to laboratory-based international normalized ratio [INR] testing and clinical management. 
Purpose: To determine clinical outcomes of the use of POCDs for OAT management by performing a meta-analysis. Previ-
ous meta-analyses on POCDs have serious limitations. 
Data sources: PubMed, the Cochrane Library, DIALOG, MEDLINE, EMBASE, BIOSIS Previews and PASCAL databases. 
Study selection: Randomized controlled trials of patients on long-term OAT, comparing anticoagulation monitoring by 
POCD with laboratory INR testing and clinical management. 
Data extraction: 1) rates of major hemorrhage; 2) rates of major thromboembolic events; 3) percentage of time that the pa-
tient is maintained within the therapeutic range; 4) deaths. Outcomes were compared using a random-effects model. Sum-
mary measures of rates were determined. The quality of studies was assessed using the Jadad scale. 
Data synthesis: Seventeen articles (16 studies) were included. Data analysis showed that POCD INR testing reduced the 
risk of major thromboembolic events (odds ratio [OR] = 0.51; 95% confidence interval [CI] 0.35–0.74), was associated 
with fewer deaths (OR = 0.58; 95% CI = 0.38–0.89), and resulted in better INR control compared with laboratory INR 
testing. No significant difference between the two management modalities with respect to odds ratios for major hemor-
rhage was found. 
Limitations: Quality scores varied from 1 to 3 (out of a maximum of 5). Only 3 studies defined how thromboembolic events 
would be diagnosed, casting doubt on the accuracy of the reporting of thromboembolic events. The studies suggest that only 
24% of patients are good candidates for self-testing and self-management. Compared with patients managed with labora-
tory-based monitoring, POCD patients underwent INR testing at a much higher frequency and received much more inten-
sive education on OAT management. 
Conclusions: The use of POCDs is safe and may be more effective than laboratory-based monitoring. However, most pa-
tients are not good candidates for self-testing and self-management. Patient education and frequency of testing may be the 
most important factors in successful PODC management. Definitive conclusions about the clinical benefits provided by self-
testing and self-management require more rigorously designed trials.   
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RAL  ANTICOAGULANTS  IN  THE  FORM  OF  
 vitamin K antagonists are widely used for the 
prevention and treatment of thromboembolic 
events  in  the  presence  of  various  clinical  conditions. 
Long-term use is typically required for high-risk groups 
with  particular  conditions  such  as  mechanical  heart 
valves,  chronic  atrial  fibrillation,  venous  thromboem-
bolism, acute myocardial infarction, stroke, and periph-
eral arterial occlusion.1,2 For many of these indications, a 
person  must  continue  on  oral  anticoagulant  therapy 
(OAT) for life.3,4 In view of the aging of the population 
and an associated increase in the prevalence of atrial fib-
rillation  and  venous  thromboembolism,  it  is  expected 
that more patients will need OAT in the future. Evidence 
suggests that OAT reduces the incidence of thromboem-
bolic  complications  (venous  and  arterial  thrombosis) 
and associated mortality and morbidity in these patient 
populations.5  
  However, vitamin K antagonists have a narrow “thera-
peutic window,” or range of clinical effectiveness. Excessive 
anticoagulation confers an increased risk of bleeding, while 
sub-therapeutic  anticoagulation  is  associated  with  an  in-
creased risk of stroke and other thromboembolic events.6,7 
Unfortunately,  the  biological  effect  of  the  vitamin  K  an-
tagonists varies from one patient to another and within in-
dividual patients over time.5 For this reason, patients need 
regular  monitoring  of  the  international  normalized  ratio 
(INR), which is usually determined in a hospital or outpa-
tient laboratory facility by a venipuncture sample processed 
in  the  lab.  This  can  be  inconvenient  with  respect  to  the 
blood sampling procedure and the time spent going for a 
laboratory test.1,2 Point-of-care devices (POCDs) for moni-
toring  long-term  OAT  were  introduced  in  the  1990s. 
POCDs are portable and require only a drop of blood from a 
fingertip  puncture.  In  some countries, such as Germany, 
self-testing and self-management with POCDs are widely 
employed, but in most countries uptake has been limited.8,9 
  The POCD technology makes it possible for patients on 
long-term OAT to self-monitor and self-manage their OAT. 
Those  who  manage  OAT  programs  need  to  know  how 
POCDs  compare  in  effectiveness  and  cost-effectiveness 
with standard laboratory tests. The objective of this meta-
analysis was to assess the clinical implications of POCD use 
for OAT monitoring as well as any potential limitations of 
the  available  data.  Our  meta-analysis  was  intended    to 
overcome weaknesses in previous studies, including the in-
clusion  of  few  studies  and  the  inclusion  of  studies  that 
should have been excluded from a meta-analysis, and  to 
present results by length of follow-up rather than by num-
bers of events per patient enrolled; this last consideration is 
important  because  the  number  of  events  per  year  gives 
physicians a better indication of the safety and effectiveness 
of point-of-care devices. 
Methods 
Literature search strategy. We obtained published lit-
erature  by  cross-searching  the  DIALOG,  MEDLINE, 
EMBASE, BIOSIS Previews and PASCAL databases. There 
were no year or language restrictions. A broad search strat-
egy with appropriate descriptors and keywords was used, in 
combination with a filter, to restrict results to controlled 
trials, meta-analyses and systematic reviews. We also ran 
parallel searches on PubMed and the Cochrane Library.  
  The original search was performed in July 2005. Regular 
alerts were established on the MEDLINE, BIOSIS Previews 
and  EMBASE  databases  to  capture  new  studies  up  to 
March 2007. Searches in the Cochrane Library were up-
dated regularly. We obtained grey literature by searching 
the websites of regulatory agencies, health technology as-
sessment agencies, and near-technology assessment agen-
cies. Specialized databases such as the NHS Centre for Re-
views and Dissemination at the University of York, Eng-
land,  and  the  Latin  American  and  Caribbean  Center  on 
Health Sciences Information (LILACS), were also searched. 
The  following  professional  associations’  web  and  confer-
ence  sites  were  searched  for  additional  information: 
Thrombosis  Interest  Group  of  Canada,  Canadian 
Cardiovascular  Society,  American  College  of  Cardiology, 
American Society of Hematology, and European Society of 
Cardiology.  Non-randomized  controlled  trials  were 
included in the literature search in view of their potential 
use in other sections of the report.  
Selection criteria and method. Studies that were in-
cluded met the following selection criteria: 
Study design: randomized controlled trial (RCT) 
Population  group:  patients  on  long-term  (at  least  3 
months)  OAT  (no  a  priori  restrictions  on  age  or  mental  
capacity) 
Interventions:  anticoagulation  monitoring  by  POCD; 
this  could  include  POCD  testing  at  an  anticoagulation 
clinic, POCD self-testing by the patient, POCD self-testing 
plus  self-management  and  control,  or  any  other  POCD 
management strategy 
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Comparators: usual care (venipuncture blood draw for 
an INR laboratory test, with management provided by an 
anticoagulation clinic or individual practitioner) 
Outcomes: studies must have reported on at least one of 
the following: 
•  Rates of major hemorrhage, where “major” was defined 
as resulting in death, or where hemorrhage was clinically 
overt and showed one of the following: critical site in-
volvement (intra-cranial, retroperitoneal, intraocular, in-
traspinal, or pericardial); drop in hemoglobin of ≥ 2.0 
g/dL; need for transfusion of > 2 units of packed red 
blood cells; or a bleeding index of > 2.0 (the number of 
units of packed red cells or whole blood transfused plus 
the hemoglobin values before the bleeding episode mi-
nus the hemoglobin values after the episode). 
•  Major thromboembolic event rates, noting whether the 
study required objective diagnostic tests for venous and 
arterial  thromboembolic  complications.  Transient 
ischemic attacks were considered to be minor throm-
boembolic  events  and  were  included  in  a  secondary 
analysis to evaluate all thromboembolic events. 
•  Percentage of time the patient’s blood was within the 
normal therapeutic INR range according to a method 
described by Rosendaal and colleagues.10 The Rosen-
daal algorithm is used to calculate the time that a pa-
tient stayed in a predetermined INR interval. The algo-
rithm assumes a linear increase or decrease between 2 
consecutive INR determinations.10 
Reports were excluded if they were duplicate reports, pre-
liminary  reports  of  data  presented  in  full,  dose-finding 
studies,  studies  in  which  oral  anticoagulants  were  com-
bined with antiplatelet drugs, or studies that did not follow 
patients  for  more  than  3  months.    Although  we  had 
planned  to  exclude  data  based  on  patients  who  had  not 
been on OAT for 3 months before entering the study, we 
dropped  this  criterion  and  performed  analyses  with  and 
without these studies. 
  We assessed the retrieved references for possible inclu-
sion by evaluating the title and the abstract according to the 
selection criteria. The reviewers pilot-tested the inclusion–
exclusion criteria on 7 articles and performed a calibration 
exercise to ensure consistent application. Letters to the edi-
tor, review articles, editorials and commentaries were ex-
cluded. The remaining studies were fully assessed.  
  At least two reviewers independently reviewed each cita-
tion from the literature search. At the first stage, abstracts 
were selected independently by KC and LM. Consensus was 
reached by discussion. At the second stage, full-text articles 
were reviewed independently. Agreement on eligibility was 
achieved by discussion between the 2 reviewers. 
Data extraction. A data extraction form was developed a 
priori.  Two  reviewers  (PW,  KC)  independently  extracted 
data from eligible articles and assessed their quality using a 
standard electronic form. PW and another reviewer (LM) 
then arrived at a consensus on the extracted data and qual-
ity values through discussion.  
Strategy for quality assessment. Study quality was as-
sessed using the criteria proposed by Jadad and colleagues, 
and the adequacy of allocation concealment was evaluated 
as  appropriate  or  inappropriate  according  to  the  criteria 
proposed by Schulz and Grimes.11,12 In the Jadad system, 1 
point is scored for each of the following criteria, such that 
the total score can be anywhere from 0 to 5: randomization; 
appropriate  method  of  randomization;  double-blinding: 
appropriate method of double-blinding; and adequate de-
scription of withdrawals and dropouts. If information in the 
reports was insufficient, these issues were recorded as un-
clear or unstated. We successfully contacted authors when 
data were incomplete or missing.  
Data analysis methods. To assess the outcomes of ma-
jor  hemorrhage,  major  thromboembolic  events,  and  all 
thromboembolic events, we conducted a meta-analysis by 
calculating odds ratios and their 95% confidence intervals 
for the event rates, comparing the results for POCD testing 
and laboratory testing. All event rates were recorded with 
reference to intention to treat. A comparison of death rates 
was also performed. We used a random-effects model for 
all  comparisons  (according  to  the  method  described  by 
DerSimonian and Laird13), recognizing that its use can re-
duce the effect of larger studies relative to a fixed-effects 
model. A random-effects model allows for between-study 
variation and was chosen as the more conservative option. 
  Differences between effects were tested using a Z test, 
and  p  values  <  0.05  were  considered  to  be  significant. 
Given that a number of potential issues could influence 
the results of the meta-analysis, we planned a priori to 
evaluate  how  certain  patient  and  trial  characteristics 
would be associated with treatment effects, even in the 
absence of statistical heterogeneity in the primary analy-
sis.  For  each  comparison  group,  we  estimated  the  be-
tween-study heterogeneity using the Q statistic in the Re-
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was considered significant for p < 0.05. The I2 statistic, 
indicating the proportion of total variation attributable to 
heterogeneity,  was  also  calculated.  For  I2,  the  cut-off 
points  were  25%, 50%  and  75%  for low,  moderate and 
high heterogeneity, respectively.14 The summary measures 
of rates of major hemorrhage and thromboembolic events 
were determined using the inverse variance weighted av-
erages.  Forest  plots  were  prepared.  Funnel  plots  were 
generated  to  assess  whether  the  magnitude  of  the  ob-
served  association  was  related  to  the  variance  of  each 
study and whether there was evidence of publication bias. 
We  did  a  paired  t-test  of  mean  percentage  time  in  the 
therapeutic range for the control and intervention groups.  
Preplanned subgroup analysis. Although our primary 
analysis was to pool all studies, we also performed 4 sub-
group analyses. The first subgroup included studies that 
required patients to be on OAT for more than 3 months 
before study entry. The second was to include only self-
management studies; the third was to analyze only studies 
that described the requirement for objective tests to diag-
nose major thromboembolic events;  and the fourth in-
cluded only studies that scored ≥ 3 on the Jadad assess-
ment tool. 
Results 
Quantity of research available. We identified 439 cita-
tions in our initial search. Routine updates yielded an addi-
tional 13 citations for a total of 452 (Fig. 1). Of these 452 ci-
tations, 409 did not meet the selection criteria and were ex-
cluded, leaving 43 (39 from the initial search and 4 from 
the updated searches). Two were added for reconsideration 
after the study criteria were revised to include studies in 
which patients had been on OAT for < 3 months at the start 
of the study. We retrieved 46 potentially relevant articles 
for  further  review.  Of  these,  we  excluded  29  articles,15-43 
leaving 17 relevant articles describing 16 unique RCTs.44-
59,60 One RCT was reported in 2 publications.50,51 These arti-
cles by Koertke and colleagues were not duplicates because 
they reported different aspects of the RCT but informed the 
data extraction for the same study. The Gadisseur article 
provided 2 sets of data because the authors compared self-
test  plus  self-management  and  self-test  plus  clinic  man-
agement to routine care.47 
  Of  the  11  articles  that  were  excluded  on  the  basis  of  
study  design,  4  were  reviews.22–25  Five  articles  were  ex-
cluded because the intervention used was inappropriate for 
our review.26–29,43 For example, although POCD testing was 
used in some studies, the patients were managed on the ba-
sis of results from laboratory testing, not POCD testing. As 
a result, no true comparison could be made with those pa-
tients in a group undergoing laboratory testing because this 
study  design  could  miss  results  related  to  management 
based on POCD testing. One article was excluded on the ba-
sis  of  the  study  population,30  1  on  the  basis  of  outcome 
measures,36  and  3  because  they  were  at  the  protocol 
stage.31–33 Three were duplicates of excluded articles,34,35,37 
and 5 were duplicates of included articles, and so they were 
also excluded.38–42 
Study characteristics. Table 1 summarizes the charac-
teristics  of the studies and demonstrates  their variability 
with regard to observation periods, mean age of patients, 
and indication for anticoagulation. It was not possible to 
break down study outcomes according to the indication for 
anticoagulation. We found 12 studies that compared self-
monitoring plus self-management to routine anticoagula-
tion control. In 9 studies, only patients who had been on 
OAT for ≥ 3 months were enrolled; in 7 studies, patients 
were enrolled from the time of initiation of anticoagulation 
or the time could not be determined.46,50,51,53,56–59 The Co-
aguchek  (Roche  Diagnostics,  Mannheim,  Germany)  was 
used in 14 studies, and the ProTime Microcoagulation Sys-
tem (International Technidyne Corporation, USA) in 2. Ta-
ble 2 summarizes the outcome data from eligible trials. 
Data  analysis  and  synthesis.  The intervention  group 
comprised 2,144.6 patient-years of observation, while the 
control group comprised 2,316.1 patient-years. For all stud-
ies, there were significantly fewer major thromboembolic 
events in the POCD testing group than in the routine care 
group (OR = 0.51; 95% CI 0.35–0.74). This statistically sig-
nificant difference was also observed in all 4 of the other 
subgroups (Table 3). The odds ratios for all thromboem-
bolic events were similar. Death from any cause was signifi-
cantly less likely in the POCD testing group (OR = 0.58; 
95% CI 0.38–0.89) when all eligible studies were pooled, 
and this remained significant in all other analyses except 
those that included only 3 studies (i.e., those that defined 
the  objective  diagnostic  criteria).  For  major  hemorrhage, 
the odds ratio was not significantly different between the 
POCD testing group and the routine testing group in any of 
the analyses (OR = 0.78; 95% CI 0.53–1.14 for the analysis 
of all studies).  The  percentage time  in therapeutic range 
was significantly better for the POCD group in all 4 relevant 
analyses (Table 3). For the “all studies” analysis, the mean 
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Table 1: Study characteristics 
Mean age 
(years)   Gender (M/F)  
Author  Country  IG  CG 
Observation 
period  IG   CG  IG  CG  Indication 
Cromheecke et al
44  Netherlands  SM  ACC  3 mo  42  42  28/17  25/19  AF, MV,VTE 
Fitzmaurice et al
45  UK  SM  PC or HACC  12 mo  64  66  400/217*  400/217*  AF, MV,VTE, O 
Gadisseur et al
47 **  Netherlands 
SM 
STPOC 
ACC 
ACC 
26 wk 
26 wk 
53.9 
54.8 
62 
62 
36/11 
40/12 
110/51 
110/51 
AF, MV,VTE, O 
AF, MV,VTE, O 
Horstkotte et al 
48  Germany  SM  PC  NR  NR  NR  NR  NR  MV 
Khan et al
49**  UK  STPOC 
ACC and 
education  6 mo  71  73  26/14  19/20  AF 
Koertke et al
50† 
Koertke et al
51  Germany  SM  PC  ≤ 51 mo  62.5*  62.5*  394/206*  394/206*  MV 
Menendez-Jandula et 
al
52  Spain  SM  ACC  up to 17 mo  61–65  63–66  190/178  201/168  AF, MV,VTE, O 
Shiach et al
54  UK  CPOC  HACC  6 mo  NR  NR  NR  NR  NR 
Sidhu et al
55  Ireland  SM 
HACC or 
PC  2 y  61.0  60.8  27/24  19/30  MV 
Beyth et al
57‡  US  STPOC  PC  up to 6 mo  74.9  74.5  74/89  95/67  AF,MV,VTE,O 
Claes et al
58**
‡  Belgium  STPOC 
PC and 
education  6 mo  70.2*  70.2*  455/379*  455/379* 
52% AF, 
MV,VTE, O 
Fitzmaurice et al
46**‡  UK  NPOC  PC  12 mo  NR  NR  NR  NR  AF, MV,VTE, O 
Sawicki et al
53‡  Germany  SM  ACC or PC  6 mo  55  55  64/26  62/27  > 80% MV 
Sunderji et al
59‡  Canada  SM  PC  up to 8 mo  57.6  62.3  44/25  54/16 
64% MV, 29% 
AF, VTE 
Voller et al
56‡  Germany  SM  PC  up to 19 mo  64.6  64.1  72/29  62/39  AF 
IG = intervention group. CG = control group. *For overall study; not reported for control or intervention group; **Multiple comparisons, but for analysis and figures in 
this table, used routine care as control group; 
†Used both papers to obtain data used in the analysis; 
‡Studies included patients who had OAC therapy for < 6 
months; ACC = specialized anticoagulation clinic; AF = atrial fibrillation; CPOC = dosed by physician in clinic, based on POC result; HACC = hospital anticoagulation 
clinic; MV = mechanical valve; NR = not reported; O = others; PC = primary care; PCPOC = primary care with POC used for INR determination; NPOC = nurse 
dosed in a clinic with INRs determined by POC; SM = self-testing with POC and dosing by patient; STPOC = self- or family-member testing with POC, but clinic pro-
vided dosing; VTE = venous thromboembolism 
 
 
73% (95% CI 69%–76%) versus 62% (95% CI 59%–65%, p 
= 0.004) for the routine care group. Figures 2 to 5 show 
Forest plots for major hemorrhage, major thromboembolic 
events,  all  thromboembolic  events,  and  death.  Figure  6 
shows the funnel plot for all thromboembolic events, which 
appears to be symmetrical and does not give an indication 
of publication bias. Figure 7 shows a funnel plot for major 
hemorrhage  that  suggests  the  possibility  of  publication 
bias. Figures 2 to 5 also provide information for assessing 
heterogeneity  using  Q  and  I2  statistics.  This  indicates  a 
small effect of heterogeneity on the meta-analysis. The I2 
values for major hemorrhage, major thromboembolism, all 
thromboembolism and death were 0%. When we analyzed 
the  studies  according  to  whether  patients  included  had 
 
been on OAT for more than 3 months or for less than 3 
months, these heterogeneity values did not change. 
  We  had  hoped  to  be  able  to  compare  quality-of-life 
(QoL)  scores  between  studies,  but  QoL  was  not  uni-
formly measured, and  when it was  measured different 
tools  were  used.  Five  studies  planned  and  performed 
formal  evaluations.  One  used  the  EuroQol49  and  re-
ported no significant changes or differences between the 
study groups from study inception to completion.  Two 
used the same 40-item structured questionnaire: Crom-
heeke44 demonstrated significant differences in 5 catego-
ries,  in  favour  of  the  self-management  group,  and 
Sawicki53  demonstrated  similar  findings  with  the  most 
pronounced  improvements  in  general  treatment R e s e a rc h                                                                                                                                           W e l l s   et al 
Open Medicine 2007;1(3):e131–46 
 
satisfaction scores and distress scores. Two studies used 
locally  developed  satisfaction  scales  and  demonstrated 
that patients were satisfied using POCDs, but the studies 
did not do any formal comparisons.54,59 
Subgroup analyses 
For the subgroup analysis in which we analyzed separately 
the studies that had enrolled only patients who had been on 
OAT > 3 months, we found 9 studies. In 7 studies, patients 
were enrolled from the time of initiation of anticoagulation; 
of these, 2 studies (Sawicki53 and Völler56) did not state how 
long patients had been on anticoagulants, and so it was as-
sumed that there was no 3-month minimum period. For 
arguably  the  most  important  subgroup  analysis  of  self-
testing  and  self-management  there  were  11  studies  that 
compared self-testing and self-management to routine care 
(Table 2). Four of these studies compared self-testing and 
self-management  with  primary  care  as  the  routine  man-
agement strategy, 3 compared it to hospital-based or spe-
cialized anticoagulation clinic care and 4 compared it to ei-
ther  primary  care  or  anticoagulation  clinic  care.  In  this 
analysis the odds ratios were as follows: for major hemor-
rhage 0.75 (95% CI 0.47–1.20); for major thromboembolic 
events 0.49 (95%  CI  0.30–0.79); for all thromboembolic 
events 0.45 (95% CI 0.24–0.84); and for deaths 0.48 (95% 
CI  0.24–0.94).  For  percentage  time  in  range  the  means 
were 73% (95% CI 68%–78%) versus 62% (95% CI 60%–
65%), p = 0.016, respectively. The quality score of the 16 
studies varied from 1 to 3, with 9 attaining a score of 3 out of 
a maximum of 5 (Table 2). Two studies received a score of 1. 
Although no study was double-blinded (it could be argued 
that this is reasonable, and so the maximum quality score 
would be 3), the investigators could minimize potential bias 
by evaluating outcomes of hemorrhage and  
thromboembolic events without knowing whether patients 
underwent  POCD  testing  or  laboratory  testing.  This  was 
done in 5 studies.47,53,57,59,60 Six studies used adequate alloca-
tion concealment.44,45,52,58,59,60 Only 3 studies stated and de-
fined how thromboembolic events would be diagnosed.52,54,58 
Most studies did define a priori the criteria for major hemor-
rhage. All subgroup findings are illustrated in Figures 2–5. 
  To evaluate the potential scope for the use of POCDs, we 
considered  whether  they  were  well  tolerated  and  easily 
Table 2. Outcome data from eligible trials 
Patient-
years  
observation 
Time in therapeutic  
range  Major HE  Major TEE 
Minor 
TEE  Deaths 
  IG  CG  IG  CG  IG  CG  IG  CG  IG  CG  IG  CG 
Quality 
score 
Cromheecke et al
44  12.5  12.5  NR  NR  0  0  0  0  0  1  NR  NR  2 
Fitzmaurice et al
45  318  264 
70% 
(68.1–72.4) 
68% 
(65.2–70.6)  4  4  3  3  1  0  5  11  3 
Gadisseur et al
47 
25 
 
21.8 
74.6 
 
74.6 
66.9% 
(62.7–71.0) 
68.6% 
(63.7–73.6) 
63.5% 
(59.7–67.3) 
63.5% 
(59.7–67.3) 
0 
 
2 
1 
 
1 
0 
 
0 
0 
 
0 
0 
 
0 
0 
 
0 
NR 
 
NR 
NR 
 
NR 
2 
 
2 
Horstkotte et al
48  ?  ?  NR  NR  ?  ?  0.92 / y  3.33 / y  NR  NR  NR  NR  1 
Khan et al
49  20  20  71.1% ± 14.5%  63.2% ± 25.9%  1  0  0  NR  0  2  NR  NR  3 
Menendez-Jandula 
et al
52  368  369  64.3% ± 14.3%  64.9% ± 19.9%  4  7  3  12  1  8  6  15  2-obj** 
Shiach et al
54  9.5  10  60.9% ± 26.4%  63.4% ± 23%  NR  NR  NR  NR  NR  NR  0  0  3-obj** 
Sidhu et al
55  67  85.1  76.5% SD NR  63.8% SD NR  1  0  1  4  ND  ND  0  4  3 
Beyth et al
57*   42.5  29  58.5% SD NR  34.2% SD NR  8  17  13  20  1  1  21  26  2 
Claes et al
58*  72.9  213  NR  NR  5  9  4  13  0  0  NR  NR  3-obj** 
Fitzmaurice et al
46*  87.3  165.7  69% (66–73)  62% (53–70)  1  0  2  6  0  4  3  6  2 
Koertke et al
50†* 
Koertke et al
51  973  943  78.3% SD NR  60.5% SD NR  17  25  12  20  NR  NR  NR  NR  3 
Sawicki et al
53 *  44.4  43.9  NR  NR  1  1  0  2  1  0  1  1  3 
Sunderji et al
59 *  45.4  46.0  71.8% ± 5.5%  63% ± 5.8%  0  1  0  2  0  0  0  0  3 
Voller et al
56*  37.3  40.3  67.8% ± 17.6%  58.5% ± 19.8%  2  0  0  1  0  0  NR  NR  1 
IG = intervention;  CG = control group; HE = hemorrhage; TEE = thromboembolic event; NR = not reported; ND = Not defined; SD = standard deviation; *studies in-
cluded patients who had OAT therapy for < 6 months; **(obj) = paper stated objective criteria for diagnosis of thromboembolic events; 
†used both papers to obtain data 
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Table 3: Odds ratios for primary and all secondary analyses 
Analysis 
Major  
hemorrhage  Major TE  All TE  All deaths  Time in range 
All studies  0.75  (0.51–1.10)  0.48 (0.33–0.72)  0.45 (0.29–0.70)  0.54 (0.35–0.83)  69% vs 61% 
3 months anticoagulation  0.78 (0.47–1.27)  0.46 (0.26–0.80)  0.35 (0.15–0.81)  0.35 (0.18–0.71)  70% vs 64% 
Self-test, self-managed  0.76 (0.47–1.24)  0.43 (0.25–0.74)  0.35 (0.16–0.73)  0.38 (0.19–0.74)  71% vs 63% 
Used objective definitions for TE  0.83 (0.36–1.88)  0.41 (0.18–0.95)  0.33 (0.15–0.73)  0.39 (0.15–1.02)  ND 
Quality scores ≥ 3**  0.78 (0.48–1.28)  0.53 (0.31–0.91)  0.65 (0.29–1.48)  0.36 (0.14–0.93)  71% vs 64% 
**No studies had a quality score of  > 3; ND = not done; too few studies; TEE = thromboembolic event. 
 
 
employed. We looked for data on patient eligibility, agree-
ment to consent, and withdrawal from studies. This is most 
relevant for the 11 studies in which patients were using the 
POCD for self-management. Three studies did not provide 
these  data.48,56,58  The  studies  that  did  report  these  data 
showed the following:  
•  With respect to the proportion of patients deemed eli-
gible from a group of consecutive patients, in 9 studies 
16% to 40% of patients were deemed unsuitable to use 
the POCD device, and most studies reported closer to 
40% as unsuitable. 
•  In  7  of  the  11  studies,  10%  to  28%  of  the  patients 
dropped out after being randomly assigned to use the 
POCD and attempting the training program. 
•  Seven studies reported that 8% to 19% abandoned the 
use of the POCD after the study began, compared with 
0% to 6% who withdrew in the routine care groups. 
Discussion 
Our study reviewed 16 RCTs comparing POCD testing to 
routine  anticoagulation  monitoring  care  in  a  hospital  or 
laboratory. Of those, 11 compared the use of POCDs for self-
management and self-monitoring with routine anticoagula-
tion monitoring. The latter comparison is the most relevant 
from the perspective of patient’s convenience of care, and 
the data in these trials suggest that POCDs result in signifi-
cantly fewer major thromboembolic events. The odds ratio 
for major hemorrhage was 0.78, but the 95% confidence in-
terval crossed 1 and therefore must be considered similar 
between the 2 groups. Insufficient data were provided in 
these studies to determine whether these differences were 
related  to  duration  of  time  that  the  patient  was  over-
anticoagulated  or  under-anticoagulated  in  respective 
groups. All results were unchanged regardless of the sub-
group analysis performed. For all analyses, the comparison 
of percentage time in range between the POCD group and 
the control group demonstrated superiority with POCD use.
  To test the robustness of the data we performed several 
subgroup  analyses.  One  included  only  patients  who  had 
been on OAT for ≥ 3 months. We were initially concerned 
that  including  patients  who  were  not  yet  stable  on  OAT 
could bias the results against the use of POCDs, given the 
known interactions with heparin and the difficulty in first 
achieving  INR  control.61  Our  subgroup  analysis  showed 
that the results were essentially the same, regardless of the 
time that patients were on OAT at baseline. The odds ratios 
were also similar whether we included all studies (i.e., any 
POCD testing compared to routine INR testing) or just self-
test  plus  self-management  comparisons.  The  outcomes 
were unchanged regardless of who performed the dosing in 
the POCD groups.  The summary data suggest that POCDs 
are advantageous. However, in all studies, the frequency of 
INR monitoring was higher in the POCD group than with 
routine anticoagulation monitoring. In most cases, the fre-
quency of testing was dictated by the study protocol. It re-
mains  unknown  whether  similar  frequent  monitoring  in 
routine  care  would  eliminate  these  differences.  It  is  also 
unknown  whether  this  rigorous  frequency  of  monitoring 
using POCDs would persist outside the study setting. It is 
possible  that  patients  who  self-manage  may  lose  regular 
contact with their physician. The implications of this are 
unknown, but when assessed against the critical endpoint 
of death, it does not seem to be a disadvantage. It should be 
noted  that  we  calculated  odds  ratios  to  approximate  the 
relative  risk,  since  the  event  rates  were  relatively  “rare” 
(some take this as < 10%), and so the odds ratio approxi-
mation of the relative risk is good. The odds ratio will al-
ways be further from the neutral point of 1 than the relative 
risk (i.e., it is a less conservative measure), so the results 
should be interpreted with this in mind. 
  These findings are subject to certain limitations. First, 
the study methods were found to be less than ideal. The R e s e a rc h                                                                                                                                           W e l l s   et al 
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highest-quality score for any of the publications was 3, no 
study was double-blinded, and in many studies it was im-
possible to categorize what happened to the patients who 
withdrew. In all studies, the withdrawal rates of the POCD 
testing groups were higher than those of the routine testing 
groups. In most studies, thromboembolic events were not 
evaluated in a blinded and objective manner. This intro-
duces the risk that the summary estimates may be biased. 
However, it is perhaps unreasonable to suggest in studies of 
this  nature  that  double-blinding  would  be  possible,  and 
therefore  in  our  analysis  we  categorized  studies  with  a 
Jadad score of at least 3 as “high quality.”  
 
  Second, the criteria for patients’ eligibility for inclusion 
into the individual clinical trials and the high withdrawal 
rates are such that it is difficult to determine generalizabil-
ity. It seems that the inclusion–exclusion criteria for the in-
dividual trials resulted in the exclusion of  many  patients 
deemed unsuitable for POCD self-testing before randomi-
zation, in addition to many such patients declining the invi-
tation to participate. Perhaps more importantly, many pa-
tients  failed  to  complete  POCD  training,  and  many  who 
completed  training  subsequently  dropped  out.  An  upper 
bound of 24% of OAT patients could be eligible for self-
testing  or  self-management  with  POCD.36  Consequently, 
the results of our meta-analysis may apply only to selected 
patients. 
  Third, the INR test frequency was much higher in the 
POCD  testing  strategies:  INRs  were  performed  approxi-
mately weekly versus monthly in the standard group. Fur-
thermore,  the  POCD  group  underwent  3  2-hour,  small-
group education sessions in most studies, whereas no spe-
cial education was provided to the standard care groups. 
  The final limitation of these studies is that there is no de-
scription of the frequency with which warfarin was with-
drawn  for  surgical  procedures  or  other  interventions.  As 
such, we have no way of knowing how many of the throm-
boembolic or hemorrhagic events could have been related 
to this phenomenon. It has been clearly documented that 
hospitalization creates the greatest risk of poor anticoagula-
tion  control,  and  there  is  a  suggestion  that  the  risk  of 
thrombosis and hemorrhage is highest around the time of 
hospitalization  of  patients  on  oral  anticoagulant  therapy. 
Although these studies are all randomized, without this in-
formation it is difficult to know if there are discrepancies 
between  the  POCD  group  and  the  routine  care  group.64 
These limitations make it impossible to determine what ef-
fects  the frequency of  monitoring,  patient education, the 
POCD, or the patient selection may have on the outcomes.60 
  Although information on quality of life and patient satis-
faction with the POCDs was collected, we were unable to 
provide quantitative summary measures of these factors. A 
qualitative analysis of the data suggest that, in general, pa-
tients were at least as satisfied with self-management using 
a POCD as with receiving care at an anticoagulation clinic, 
and that some preferred using a POCD. These patients were 
good  candidates  for  using  a  POCD,  having  been  self-
selected or selected by a health care researcher.   
  This report is not the first systematic review to compare 
POCD testing with laboratory testing for the managementR e s e a rc h                                                                                                                                           W e l l s   et al 
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Figure 5: Forest plot, death 
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Figure 6: Funnel plot, all thromboembolic events 
 
 
 
Figure 7: Funnel plot, major hemorrhage 
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of patients on OAT. Five systematic reviews have been pub-
lished,  but  all  have  limitations.22,24,62,63  The  most  recent 
analysis by Heneghan and colleagues suggests that POCD 
testing resulted in significantly fewer major hemorrhages, 
thromboembolic events, and deaths than conventional INR 
testing.61 The Heneghan analysis involved the examination 
of 14 studies, included 3 that we considered to be ineligible: 
one compared POCD testing only with other POCD testing 
(i.e., inappropriate comparison for their analysis), one did 
not use POCD test results for OAT management, and the 
third followed patients for only 8 weeks.21,27,43  Our report 
also included 5 articles that were either excluded or not yet 
published  at  the time  of  Heneghan’s analysis.45,46,54,58  Fi-
nally, the summary data used  by these authors reported 
events per patient enrolled and not by length of follow-up, 
as we did. As such, the rates we report are more accurate 
and more relevant.  With the additional studies and analy-
sis we used, we came to similar conclusions with respect to 
the rate of all thromboembolic events, deaths and time in 
therapeutic range. Heneghan did not report separately on 
the  more  relevant  outcome  of  major  thromboembolic 
events. Contrary to Heneghan’s study our analysis did not 
detect  a  significant  difference  for  the  outcome  of  major 
hemorrhage. 
  Our meta-analysis suggests that using POCDs to manage 
OAT results in significantly fewer thromboembolic events 
and better INR control than laboratory-based INR testing. 
Under usual care, warfarin therapy requires regular labora-
tory monitoring of the INR, coupled with frequent physi-
cian–patient contact for dosage adjustment to ensure effi-
cacy and safety.9 The usual-care method can be cumber-
some and inconvenient for the patient and the physician. 
There is also a potential for dosing errors resulting from 
misinterpretation of information conveyed by the physician 
or delays in contacting the patient.9  This, plus faster test re-
sults, greater convenience and more frequent testing, are 
plausible reasons  for  the  incremental  health  benefits  ob-
served with POCD use. 
  Unfortunately, the studies designed to date do not allow 
a  determination  of  why  POCD  care  is  superior.  Further 
randomized  controlled  trials  are  needed  to  determine 
whether it is patient education or frequency of testing that 
provides  superior  outcomes.  Widespread  adoption  of 
POCD monitoring at this time would be premature. 
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